2026 年至 2032 年干粉吸入器 (DPI) 市场按产品类型、应用、销售管道和地区划分

干粉吸入器（DPI）市场评估 - 2026-2032

市场快速扩张的驱动因素包括慢性呼吸系统疾病盛行率的不断上升、DPI 的技术发展以及自我治疗趋势的日益增长。据 Verified Market Research 分析师称，干粉吸入器市场预计在 2024 年价值约为 184 亿美元，预计在预测期内将达到 244.7 亿美元的估值。

呼吸系统疾病发病率的上升、DPI设备技术的改进以及患者对快速有效吸入疗法的需求推动了干粉吸入器（DPI）市场的强劲扩张。基于此，预计2026年至2032年市场将以3.6%的复合年增长率成长。

干粉吸入器（DPI）市场：定义/概述

干粉吸入器 (DPI) 是医疗设备。与使用推进剂排出药物的传统吸入器不同，DPI 利用患者的呼吸来吸入粉末。它们被广泛用于治疗气喘、慢性阻塞性肺病(COPD) 和其他肺部疾病等呼吸系统疾病，因为它们提供了一种将支气管扩张剂、皮质类固醇和其他药物直接输送到呼吸道的便捷有效的方法。

影响 DPI 市场成长轨迹的关键驱动因素有哪些？

慢性阻塞性肺病(COPD)、气喘和囊肿纤维化等呼吸系统疾病的盛行率不断上升是 DPI 市场的主要驱动力。同样，《2018 年全球气喘报告》估计，气喘影响全球超过 3.39 亿人。需要吸入治疗的患者数量不断增长，推动了对有效且便利的 DPI 设备的需求。

与标准定量吸入器 (MDI) 和雾化器相比，DPI 具有许多优势，包括便携性、使用方便性和无需推进剂。这些优势使得DPI对患者更具吸引力，从而导致更高的接受度。 《气雾剂医学与肺部药物输送杂誌》（2019 年）发表的一项调查发现，89% 的患者更喜欢 DPI 而不是定量吸入器，因为它们易于使用且便于携带。

根据联合国统计，世界人口正在老化，预计到 2050 年，60 岁及以上人口的数量将增加一倍。老年人更容易受到呼吸道感染疾病，因此对更易于使用且对该患者群体更有效的 DPI 设备的需求日益增长。

此外，DPI 设备设计、药物配方和製造流程的不断进步正在提高这些产品的效率和使用率。例如，多剂量和呼吸驱动的DPI的开发提高了患者的依从性和便利性。例如，发表在《BMJ Open》上的一项研究发现，在英国将 10% 的计量吸入器 (MDI) 替换为干粉吸入器 (DPI) 每年可减少 58,000 吨碳排放。

干粉吸入器（DPI）市场中的公司面临哪些挑战？

正确的吸入技术对于使用 DPI 有效输送药物至关重要，但这对于小孩、老人和协调性差的患者来说可能比较困难。不一致的呼吸技巧会导致输送到肺部的药物减少，进而影响治疗的效果。

创建稳定有效的 DPI 配方非常困难。粉末必须足够细才能有效吸入，同时具有适当的流动特性才能达到最佳分散。此外，有些药物具有吸湿性，可能会积聚周围的水分，从而影响其在 DPI 内的稳定性和功能。

此外，DPI 还与其他吸入技术（如压力定量吸入器 (MDI) 和雾化器）竞争。 MDI 因其易于使用而受到青睐，而雾化器适合那些难以掌握吸入技术或需要更高剂量药物的人，从而限制了 DPI 在某些领域的市场成长。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查方法

第二章执行摘要

• 主要发现
• 市场概览
• 市集亮点

第三章市场概述

• 市场规模和成长潜力
• 市场趋势
• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析

第四章 干粉吸入器（DPI）市场：按剂型

• 皮质类固醇
• 支气管扩张剂
• 抗生素
• 组合药物

5. 干粉吸入器（DPI）市场（按地区）

• 北美洲
• 欧洲
• 亚太地区
• 拉丁美洲
• 其他的

第六章 干粉吸入器（DPI）市场：依应用

• 气喘
• 慢性阻塞性肺病（COPD）
• 囊肿纤维化
• 其他呼吸系统疾病

第七章区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯聯合大公国

第八章市场动态

• 市场驱动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第九章 竞争态势

• 主要企业
• 市场占有率分析

第十章 公司简介

• GlaxoSmithKline plc
• AstraZeneca plc
• Boehringer Ingelheim International GmbH
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Cipla Inc.
• Merck & Co., Inc.
• 3M Pharmaceuticals
• Hovione
• MannKind Corpo

第十一章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第十二章 附录

• 简称列表
• 来源和参考文献

Dry Powder Inhaler (DPI) Market Valuation - 2026-2032

The increasing prevalence of chronic respiratory diseases, technological developments in DPIs, and the growing inclination towards self-medication are all contributing to the market's rapid expansion. According to the analyst from Verified Market Research, the dry powder inhaler market is estimated to reach a valuation of USD 24.47 Billion over the forecast subjugating around USD 18.4 Billion valued in 2024.

The growing rates of respiratory illnesses, improved DPI device technology, and patient demand for quick and efficient inhalation treatment are all contributing to the market's strong expansion for dry powder inhalers, or DPIs. It enables the market to grow at a CAGR of 3.6% from 2026 to 2032.

Dry Powder Inhaler (DPI) Market: Definition/ Overview

A Dry Powder Inhaler (DPI) is a medical device that administers medication to the lungs in the form of dry powder. Unlike regular inhalers, which utilize a propellant to dispense medication, DPIs use the patient's breath to inhale the powder. These devices are widely used to treat respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other lung diseases, as they provide a convenient and effective way to deliver bronchodilators, corticosteroids, and other medications directly to the respiratory tract.

What are the Key Drivers Shaping the Growth Trajectory of the DPI Market?

The rising prevalence of respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis is a significant driver of the DPI market. Similarly, the Global Asthma Report 2018 predicts that asthma affects more than 339 million individuals worldwide. The expanding number of patients requiring inhalation therapy is driving the demand for effective and convenient DPI devices.

DPIs have various advantages over standard metered-dose inhalers (MDIs) and nebulizers, including portability, convenience of use, and the elimination of propellants. These advantages make DPIs more enticing to patients, resulting in higher adoption. According to research published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery (2019), 89% of patients preferred DPIs to metered-dose inhalers because of their ease of use and mobility.

The global population is aging, with the number of individuals aged 60 and older anticipated to double by 2050, according to the United Nations. Older persons are more vulnerable to respiratory infections, increasing the demand for DPI devices that are simpler to use and more effective for this patient population.

Furthermore, continuous advancements in DPI device design, medication formulations, and manufacturing processes improve the efficiency and use of these products. For example, the development of multi-dose DPIs and breath-actuated DPIs has increased patient compliance and convenience. For instance, according to a study published in BMJ Open, switching 10% of metered-dose inhalers (MDIs) to dry powder inhalers (DPIs) in the UK could reduce carbon emissions by 58,000 tons annually.

What are the Challenges Faced by Companies in the Dry Powder Inhaler (DPI) Market?

Proper inhaling methods are essential for effective medication delivery with a DPI, which can be challenging for small children, elderly patients, and individuals with coordination issues. Inconsistent breathing procedures cause less medication accumulation in the lungs, potentially jeopardizing therapy efficacy.

Creating stable and effective DPI compounds is difficult. The powder should be fine enough for efficient inhalation while also having appropriate flow characteristics for optimum dispersion. Furthermore, some drugs are hygroscopic, accumulating moisture from their surroundings, affecting their stability and function within a DPI.

Furthermore, DPIs compete with other inhalation technologies, such as pressurized metered dosage inhalers (MDIs) and nebulizers. MDIs are recommended for their ease of use, whereas nebulizers are appropriate for people suffering from inhalation techniques or requiring high medicine doses, which limits market growth for DPIs in certain segments.

Category-Wise Acumens

How Does the Dominance of Capsule-based DPIs Contribute to the Overall Market?

According to VMR Analysis, the capsule-based segment is estimated to hold the largest market share during the forecast period. Capsule-based DPIs are designed to be simple and user-friendly for patients. They frequently have a simple loading mechanism that requires little effort to prepare the dose. Furthermore, capsule-based devices are small and lightweight, which improves portability and convenience for patients on the move.

Capsule-based DPIs provide better dosage precision than other device types. The pre-metered capsules ensure that each dose includes the exact amount of medication, reducing the risk of under- or overdosing. This precision contributes to improved therapeutic efficacy and patient outcomes.

Furthermore, DPI capsules work well with a wide range of respiratory drugs, including bronchodilators, corticosteroids, and combination therapy. This adaptability enables healthcare providers to modify treatment strategies to particular patient demands, resulting in the widespread use of capsule-based devices.

What Drivers Support the Maximum Usage of DPI in Treating COPD?

The chronic obstructive pulmonary disease (COPD) segment is estimated to dominate the dry powder inhaler market during the forecast period. COPD is a prominent cause of illness and mortality worldwide, with a large and increasing prevalence. The World Health Organization estimates that over 65 million people suffer from COPD globally. This vast patient population creates a demand for effective inhalation medicines for COPD therapy, such as DPIs.

COPD is primarily controlled with inhalation medicines, which effectively deliver pharmaceuticals to the lungs. DPIs have been a popular alternative among COPD patients due to their portability, convenience, and ability to administer exact medicine doses precisely to the afflicted parts of the respiratory system.

Additionally, there is an increasing emphasis on preventative healthcare strategies for respiratory disorders such as COPD. DPIs serve an important role in providing targeted drug delivery, reducing exacerbations, and improving overall health outcomes for COPD patients, which has fueled their acceptance in this segment.

Country/Region-wise Acumens

What Unique Market Dynamics Contribute to North America's Leadership in the Market?

According to VMR Analyst, North America is estimated to dominate the dry powder inhaler market during the forecast period. Asthma and chronic obstructive pulmonary disease (COPD) are common respiratory disorders in North America, particularly in the United States. According to the Centers for Disease Control and Prevention, more than 25 million Americans have asthma, while an estimated 16 million people in the United States suffer from COPD. This vast patient population increases the demand for effective inhalation medicines such as DPIs.

North America, led by the United States, has a well-developed healthcare system that provides extensive access to innovative medical technologies and treatments. This allows for the adoption of innovative DPI equipment and promotes the growth of the DPI market in the region. The presence of important market participants, as well as ongoing R&D initiatives, contribute to the region's dominant position.

Furthermore, the availability of favorable payment rules for respiratory drugs and equipment increases patient access to DPIs. This, combined with the population's strong spending power, makes North America an appealing market for DPI producers, driving overall regional market growth.

What Factors Lead to Asia Pacific Experiencing the Fastest Growth in the Market?

The Asia Pacific region is estimated to exhibit the highest growth within the dry powder inhaler market during the forecast period. The Asia-Pacific region includes a sizable and expanding patient population suffering from respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. According to the Global Asthma Report 2018, the Asia-Pacific region has the most people with asthma, accounting for more than 175 million cases. This high illness burden drives the region's adoption of effective inhalation medicines such as DPIs.

Governments in the Asia-Pacific region are boosting their investments in healthcare access and infrastructure, particularly in emerging countries. This, together with increased awareness of respiratory disorders and the benefits of sophisticated inhalation devices among healthcare professionals and patients, is driving the DPI market in this region.

Furthermore, leading multinational pharmaceutical and medical device businesses are increasing their presence and manufacturing capabilities in Asia-Pacific to meet rising demand. Also, strategic collaborations between major corporations and local players are permitting the launch of innovative DPI products adapted to the needs of the regional market, which is driving the Asia-Pacific DPI market forward.

Competitive Landscape

The dry powder inhaler (DPI) market is characterized by fierce competition among leading competitors, which is driven by ongoing innovation and developments in device technology. Additionally, the rising prevalence of respiratory disorders has prompted significant investment in R&D, resulting in the launch of new formulations and combination medicines.

Some of the prominent players operating in the dry powder inhaler (DPI) market include:

GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novartis AG, Teva Pharmaceutical Industries Ltd., Cipla Inc., Merck & Co., Inc., 3M Pharmaceuticals, Hovione, MannKind Corpo.

Latest Developments

In February 2021, Catalent Inc. purchased Acorda Therapeutics Inc., expanding its DPI production capabilities and adding a commercial-stage pharmaceutical to its portfolio. This acquisition highlights the growing importance of DPI treatments in respiratory and neurological illnesses.

In April 2019, Hovione Technology acquired the rights to develop and commercialize Dr. Klaus-Dieter Beller's Papillon DPI, a revolutionary and cost-effective dry powder inhaler technology.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Dry Powder Inhaler (DPI) Market, By Formulation

• Corticosteroids
• Bronchodilators
• Antibiotics
• Combination products

5. Dry Powder Inhaler (DPI) Market, By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Rest of the World

6. Dry Powder Inhaler (DPI) Market, By Application

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Cystic Fibrosis
• Other respiratory conditions

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• GlaxoSmithKline plc
• AstraZeneca plc
• Boehringer Ingelheim International GmbH
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Cipla Inc.
• Merck & Co., Inc.
• 3M Pharmaceuticals
• Hovione
• MannKind Corpo

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References